BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CRG-150 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CRG-150\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07730125-9187@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:CRG-150: Phase 1/2 readout est. (NCT07730125)
DESCRIPTION:CRG-150\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/
 Refractory Malignancies\nEstimated primary completion: June 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/crg-150#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07730125
URL:https://assetmemo.bio/drug/crg-150#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
